STOCK TITAN

Molecular Partners to Present at SVB Leerink Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a biotech company focused on DARPin therapeutics, announced that its CEO, Patrick Amstutz, Ph.D., will be speaking at the SVB Leerink Global Healthcare Conference on February 15, 2023, at 12:00 pm ET. The presentation will provide insights into the company's clinical-stage advancements and partnerships within oncology and infectious diseases. A webcast and replay will be accessible on their official website. Molecular Partners AG aims to address challenges that existing drug modalities cannot, with several compounds in various stages of development.

Positive
  • None.
Negative
  • None.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the SVB Leerink Global Healthcare conference (Virtual).

Conference Presentation Details:

SVB Leerink Global Healthcare Conference Wednesday, February 15, 2023, at 12:00 pm ET (6:00 pm CET)

A webcast and replay of the presentation will be made available on the Molecular Partners website.

About Molecular Partners AG:

Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs

For further details, please contact:

Seth Lewis, Head of Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Antonio Ligi, Head of Communications
Zürich-Schlieren, Switzerland
antonio.ligi@molecularpartners.com
Tel: +41 79 723 36 81


FAQ

What is the date of the SVB Leerink Global Healthcare Conference for Molecular Partners AG?

The SVB Leerink Global Healthcare Conference for Molecular Partners AG is scheduled for February 15, 2023.

Who will represent Molecular Partners AG at the SVB Leerink Global Healthcare Conference?

CEO Patrick Amstutz, Ph.D., will represent Molecular Partners AG at the conference.

Where can I watch the presentation from the Molecular Partners AG conference?

The presentation will be available for viewing on the Molecular Partners AG official website after the conference.

What is the focus of Molecular Partners AG's DARPin therapeutics?

Molecular Partners AG focuses on developing DARPin therapeutics to tackle challenges in oncology and infectious diseases.

What stock symbols are associated with Molecular Partners AG?

Molecular Partners AG is listed under the stock symbols SIX: MOLN and NASDAQ: MOLN.

Molecular Partners AG American Depositary Shares

NASDAQ:MOLN

MOLN Rankings

MOLN Latest News

MOLN Stock Data

199.66M
40.33M
5.31%
0.15%
Biotechnology
Healthcare
Link
United States of America
Schlieren